

RAG Foundation and CVC successfully place additional Evonik shares

April 24, 2013

Tim Lange
Head of Investor Relations
Telefon +49 201 177-3150
tim.lange@evonik.com

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL, OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS DISCLOSURE.

Essen, April 24, 2013. RAG Foundation and funds advised by CVC Capital Partners today successfully placed additional Evonik Industries AG shares exclusively with domestic and international institutional investors via an accelerated bookbuilding. Including over-allotment option (Greenshoe) today's placement comprised 10.718 million Evonik shares at a price of 32.20 Euro per share, representing a total placement volume of 345.1 million Euro.

The placement has been conducted by Deutsche Bank Aktiengesellschaft and MainFirst Bank Aktiengesellschaft. Following the two private placements closed in February and March this year of c. 12.2 percent of Evonik shares, the free float now amounts to approximately 14.5 percent.

On April 24, 2013 the entire Evonik share capital of 466 million shares has been admitted to trading in the regulated market (Prime Standard) of the Frankfurt Stock Exchange as well as in the regulated market of the Luxembourg Stock Exchange. The start of trading of Evonik shares in the regulated market of the Frankfurt and Luxembourg Stock Exchanges is envisaged for April 25, 2013.

Disclaimer

This disclosure may not be published, distributed or transmitted in the United States of America, Canada, Australia or Japan. This disclosure does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Shares") of Evonik Industries AG (the "Company") in the United States of America, Germany or any other country. The Shares of the Company may not be

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Dr. Werner Müller, Chairman

Executive Board
Dr. Klaus Engel, Chairman
Dr. Wolfgang Colberg,
Dr. Thomas Haeberle,
Thomas Wessel,
Patrik Wohlhauser, Dr. Dahai Yu

Registered office Essen
Register Court: Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares of the Company have not been, and will not be, registered under the Securities Act.

This disclosure constitutes neither an offer to sell nor a solicitation to buy securities. There will be no public offer of securities of the Company.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In so far as forecasts or expectations are expressed in this disclosure or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this disclosure.